extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
entity-batch: update 1 entities
2026-03-16 12:45:25 +00:00 · 2026-03-16 12:45:21 +00:00 · 2026-03-16 12:43:53 +00:00
20 changed files with 45 additions and 17 deletions
--- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
+++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
@ -36,6 +36,12 @@ For value-based care models and capitated payers, this multi-organ protection cr

 SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems.

+
+### Additional Evidence (confirm)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
+
+FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. This confirms multi-organ protection extends beyond the primary endpoint - a kidney trial produced substantial cardiovascular benefits. Additive benefits when used with SGLT2 inhibitors per separate Nature Medicine analysis.
+
 ---

 Relevant Notes:
--- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md
+++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md
@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 - FDA indication expansion to T2D patients with CKD (2024)
 - Dialysis cost benchmark: $90K+/year per patient

+
+### Additional Evidence (confirm)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
+
+FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR slope less steep by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early for efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM.
+
 ---

 Relevant Notes:
--- a/entities/internet-finance/metadao.md
+++ b/entities/internet-finance/metadao.md
@ -65,6 +65,7 @@ The futarchy governance protocol on Solana. Implements decision markets through
 - **2024-01-24** — Proposed AMM program to replace CLOB markets, addressing liquidity fragmentation and state rent costs (Proposal CF9QUBS251FnNGZHLJ4WbB2CVRi5BtqJbCqMi47NX1PG)
 - **2024-01-29** — AMM proposal passed with 400 META on approval and 800 META on completion budget
 - **2024-08-31** — Passed proposal to enter services agreement with Organization Technology LLC, creating US entity vehicle for paying contributors with $1.378M annualized burn rate. Entity owns no IP (all owned by MetaDAO LLC) and cannot encumber MetaDAO LLC. Agreement cancellable with 30-day notice or immediately for material breach.
+- **2024-03-19** — Colosseum proposed $250,000 OTC acquisition of META from treasury with TWAP-based pricing and 12-month vesting; proposal passed 2024-03-24
 ## Key Decisions
 | Date | Proposal | Proposer | Category | Outcome |
 |------|----------|----------|----------|---------|
--- a/inbox/archive/2024-00-00-alea-research-metadao-fair-launches.md
+++ b/inbox/archive/2024-00-00-alea-research-metadao-fair-launches.md
@ -4,7 +4,7 @@ title: "Alea Research: MetaDAO's Fair Launch Model Analysis"
 url: https://alearesearch.substack.com/p/metadaos-fair-launches
 archived_date: 2024-00-00
 format: article
-status: processing
+status: unprocessed
 processed_date: 2024-03-11
 extraction_model: claude-3-7-sonnet-20250219
 enrichments:
--- a/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md
+++ b/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md
@ -7,9 +7,13 @@ date: 2024-05-29
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---

 ## Content
@ -38,3 +42,14 @@ Additive benefits when used with SGLT2 inhibitors (separate analysis in Nature M
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Kidney protection is where GLP-1 downstream savings are largest per-patient — dialysis prevention is the economic mechanism most favorable to the VBC cost-saving thesis
 EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for capitated payers, not just the clinical endpoint
+
+
+## Key Facts
+- FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease
+- Median follow-up was 3.4 years before early stopping
+- Trial was stopped at prespecified interim analysis due to efficacy
+- Primary composite endpoint showed HR 0.76 (P=0.0003)
+- Cardiovascular death HR 0.71 (95% CI 0.56-0.89)
+- Annual eGFR slope difference was 1.16 mL/min/1.73m2 (P<0.001)
+- FDA expanded semaglutide (Ozempic) indications to include T2D patients with CKD
+- Additive benefits observed when used with SGLT2 inhibitors per Nature Medicine analysis
--- a/inbox/archive/2025-10-06-futardio-launch-umbra.md
+++ b/inbox/archive/2025-10-06-futardio-launch-umbra.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/9kx7UDFzFt7e2V4pFtawnupKKvRR3EhV7P1Pxmc5XCQj"
 date: 2025-10-06
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-02-21-futardio-launch-forevernow.md
+++ b/inbox/archive/2026-02-21-futardio-launch-forevernow.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/9FCpb4TmNkvrgkoiJzUm5vDBnQUqzSrUvxEvESBrns46"
 date: 2026-02-21
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-02-21-rakka-sol-omnipair-rate-controller.md
+++ b/inbox/archive/2026-02-21-rakka-sol-omnipair-rate-controller.md
@ -6,7 +6,7 @@ date: 2026-02-21
 archived_by: rio
 tags: [omnipair, rate-controller, interest-rates, capital-fragmentation]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---

--- a/inbox/archive/2026-02-25-futardio-launch-donuts.md
+++ b/inbox/archive/2026-02-25-futardio-launch-donuts.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/DYKhWPc3fQTsMEg6xpKttiZFMRzr8EjkQzFPxQyVRUyt"
 date: 2026-02-25
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-02-25-oxranga-solomon-lab-notes-05.md
+++ b/inbox/archive/2026-02-25-oxranga-solomon-lab-notes-05.md
@ -6,7 +6,7 @@ date: 2026-02-25
 archived_by: rio
 tags: [solomon, YaaS, yield, audit, treasury, buyback, metadao-ecosystem]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---

--- a/inbox/archive/2026-02-28-futardio-launch-salmon-wallet.md
+++ b/inbox/archive/2026-02-28-futardio-launch-salmon-wallet.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/512ifHxPFoZa2GUHXi4mLUvJkFfBcZp4E7d1A7Y6EpGG"
 date: 2026-02-28
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-02-futardio-launch-reddit.md
+++ b/inbox/archive/2026-03-02-futardio-launch-reddit.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/HkF8CWrUYcnCjGmdhaQ2jyqfwMWioNK7PrJiAxhQx9i8"
 date: 2026-03-02
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-03-pineanalytics-metadao-q4-2025-quarterly-report.md
+++ b/inbox/archive/2026-03-03-pineanalytics-metadao-q4-2025-quarterly-report.md
@ -5,7 +5,7 @@ url: https://x.com/PineAnalytics/status/2028683377251942707
 date: 2026-03-03
 tags: [rio, metadao, futarchy, quarterly-report, financial-data]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---

--- a/inbox/archive/2026-03-04-futardio-launch-lososdao.md
+++ b/inbox/archive/2026-03-04-futardio-launch-lososdao.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/Aji1A3Fu6iBSh6kAysG9TR5o4cPB1RxzYwWqw8Xkbc5o"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-04-futardio-launch-one-of-sick-token.md
+++ b/inbox/archive/2026-03-04-futardio-launch-one-of-sick-token.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/Gdyb1kNw26gve1VqU3zRxwZJhwJd5nAQ4goKNvAQBv9K"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-04-futardio-launch-pli-crperie-ambulante.md
+++ b/inbox/archive/2026-03-04-futardio-launch-pli-crperie-ambulante.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/GmNzSXzQ3q6UCVRpBf8PkvEqoo454Qr6twWc9zuzJzBa"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-04-futardio-launch-proph3t.md
+++ b/inbox/archive/2026-03-04-futardio-launch-proph3t.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/316rXWmR84ppwS4FKfZQWPmwqQCQi4NRWCbeVwYqDPna"
 date: 2026-03-04
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-05-futardio-launch-ludex-ai.md
+++ b/inbox/archive/2026-03-05-futardio-launch-ludex-ai.md
@ -6,7 +6,7 @@ url: "https://www.futard.io/launch/95HNkVuqzStFe7B6Aw32sgkbwkHEyEsA818izKKTz776"
 date: 2026-03-05
 domain: internet-finance
 format: data
-status: unprocessed
+status: processed
 tags: [futardio, metadao, futarchy, solana]
 event_type: launch
 processed_by: rio
--- a/inbox/archive/2026-03-05-pineanalytics-futardio-launch-metrics.md
+++ b/inbox/archive/2026-03-05-pineanalytics-futardio-launch-metrics.md
@ -5,7 +5,7 @@ url: https://x.com/PineAnalytics/status/2029616320015159504
 date: 2026-03-05
 tags: [rio, metadao, futarchy, futardio, permissionless-launches]
 domain: internet-finance
-status: unprocessed
+status: processed
 claims_extracted: []
 ---

--- a/inbox/archive/2026-03-09-rakka-omnipair-conversation.md
+++ b/inbox/archive/2026-03-09-rakka-omnipair-conversation.md
@ -6,7 +6,7 @@ title: "OmniPair deep dive — mechanism design, competitive position, ecosystem
 date: 2026-03-09
 ingested: 2026-03-11
 ingested_by: rio
-status: processing
+status: unprocessed
 domain: internet-finance
 transcript_path: "~/.pentagon/voicenotes/transcripts/rakka.md"
 claims_extracted: []
Author	SHA1	Message	Date
Teleo Agents	ba1ce0a01a	extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>	2026-03-16 12:45:25 +00:00
Teleo Agents	5c1fcdc341	entity-batch: update 1 entities - Applied 1 entity operations from queue - Files: entities/internet-finance/metadao.md Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>	2026-03-16 12:45:21 +00:00
Teleo Agents	a292518951	epimetheus: mark 14 zombies processed + reset 2 stuck processing sources Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>	2026-03-16 12:43:53 +00:00